Outset Medical (OM) Stock
Dialysis equipment maker simplifying care for home and hospital. Here's the price, business snapshot, and what's worth knowing about Outset Medical in September 2026.
Outset Medical (OM) designs and manufactures haemodialysis systems intended for hospital, clinic and home settings. The company is best known for the Tablo system, which targets simplification of dialysis delivery and operational efficiency. As a small-cap medical-device business (market capitalisation provided at around $271m), Outset sits in a competitive, highly regulated healthcare segment where growth depends on clinical adoption, reimbursement policies and hospital procurement cycles. Potential upside comes from rising demand for dialysis services globally and any gains in market share for easier-to-use or lower-cost systems. Key risks include regulatory review, reimbursement pressures, execution on manufacturing and commercial scale-up, and the typical volatility of smaller, growth-oriented healthcare firms. This profile is educational and not investment advice — investors should review the company’s latest regulatory filings, recent results and consult a financial professional to assess suitability given that share values can fall as well as rise.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Outset Medical's stock with a target price of $6.25, indicating potential growth.
Financial Health
Outset Medical is generating solid revenue and cash flow, reflecting strong operational performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Adoption Opportunity
The Tablo system aims to simplify dialysis delivery, which could support commercial adoption — though uptake depends on clinical acceptance and procurement cycles.
Global Demand Trends
Ageing populations and rising chronic kidney disease suggest structural demand for dialysis, yet reimbursement and regional regulation can strongly influence outcomes.
Execution Risks
Scaling manufacturing, navigating approvals and competing with larger players are key execution challenges; small-cap stocks can be particularly volatile.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
